乳腺癌外周血SBEM和hMAM联合检测的临床意义

Detection of SBEM and hMAM in peripheral blood from patients with breast cancer and its clinical significance

目的探讨乳腺癌患者外周血乳腺小粘蛋白(SBEM)及人乳腺珠蛋白(hMAM)的表达及临床意义。方法采用酶联免疫吸附试验(ELISA)定量检测68例乳腺癌患者及20例乳腺纤维腺瘤患者及20例健康志愿者术前血清SBEM和hMAM的水平。结果乳腺癌组术前血清SBEM和hMAM水平均高于纤维腺瘤组和健康对照组(P均<0.01)。有淋巴结转移的乳腺癌患者血清中SBEM和hMAM水平明显高于无淋巴结转移者,差异均有统计学意义(P均<0.05)。Ⅲ期患者血清SBEM和hMAM水平显著高于Ⅰ+Ⅱ期患者(P均小于0.01)。结论 SBEM及hMAM特异性表达于乳腺癌外周血,有可能作为检测乳腺癌外周血微转移的标志物,有望成为判断乳腺癌患者病情发展和预后的新指标。

Objective To explore the levels of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood from patients with breast cancer and their clinical significance.Methods The levels of SBEM and hMAM in serum from 68patients with breast cancer,20patients with mammary fibroadenoma and 20volunteers were detected by enzyme-linked immunosorbent assay （ELISA）.Results Compared with breast fibroadenoma group and volunteer group,the levels of serum SBEM and hMAM in breast cancer group were much higher （P0.01）.The levels of serum SBEM and hMAM of patients with lymph node positive were significantly higher than those in the other patients （P0.05）.The levels of patients in stageⅢ were also significantly higher than those in stageⅠand stageⅡ （P0.01）.Conclusion SBEM and hMAM are specifically expressed in peripheral blood of breast cancer patients,and each of them may be marker of micrometastasis of breast cancer.They may be used as new biological indexes for judging progression and prognosis of mammary carcinoma.